Vaginal hysterectomy for the treatment of low-risk endometrial cancer: Surgical technique, costs, and perioperative and oncologic results

• Published in: Gynecologic oncology 2024-02, Vol.181, p.76-82
• Main Authors: de Souza Nobrega, Fernando, Alvarenga-Bezerra, Vanessa, Barbosa, Guilherme Bicudo, Salim, Rafael Calil, Martins, Luísa Marcella, de Cillo, Pedro Ernesto, de Moura Queiroz, Priscila, Moretti-Marques, Renato
• Format: Article
• Language: English
• Subjects: Cost-effectiveness; Endometrial cancer; Vaginal hysterectomy
• ISSN: 0090-8258; 1095-6859; 1095-6859
• DOI: 10.1016/j.ygyno.2023.12.012

This study aimed to describe an operative technique for vaginal hysterectomy (VH) and assess the costs, perioperative, and oncological outcomes for this procedure when used in the treatment of patients with low-risk endometrial cancer (LREC). A retrospective analysis of medical records was conducted on patients who underwent VH to treat precursor and invasive endometrial lesions between April 2019 and November 2021 at a single center in São Paulo, Brazil. Thirty-four patients met the inclusion criteria. The mean patient age was 61.9 years, and the mean body mass index (BMI) was 34. Obese patients (BMI ≥ 30) accounted for 77% of the sample. Preoperative functional capacity measures were Eastern Cooperative Oncology Group (ECOG) 0–1 and ECOG-2 for 91% and 9% of the patients, respectively. The mean operative time and length of hospital stay were 109 min and 1.2 days, respectively. Four patients had a conversion of the surgical route to laparotomy. No major intraoperative complications were observed. Patients who underwent surgical conversion had a greater uterine volume (227 versus 107 mL, p = 0.006) and longer operative time (177 versus 96 min, p = 0.001). The total cost associated with VH was, on average, US$ 2058.77 (R$ 10,925.91), representing 47% of the cost associated with non-vaginal routes. Twenty-eight patients received a definitive diagnosis of endometrial carcinoma; of these, three received adjuvant radiotherapy. The mean follow-up period was 34.6 months for the patients diagnosed with cancer. One case of disease recurrence occurred 16.6 months after surgery, with one death at 28.6 months of follow-up. These findings suggest that VH could be a feasible and cost-effective alternative for selected patients with LREC in low-resource settings. •The study describes a reproducible and oncologically safe technique for treating endometrial cancer via the vaginal route.•The largest series of endometrial cancer cases treated via the vaginal route in Brazil is also presented.•Safety criteria should be respected when performing vaginal hysterectomy for patients with endometrial cancer.•Vaginal hysterectomy appears to be cost-effective for the treatment of patients with low-risk endometrial cancer.•The vaginal route may serve as an alternative point of access for the treatment of patients in low-resource settings.